相关实验视频

Updated: May 15, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

慢性骨髓性白血病中的olverembatinib - 历史发展,当前状态和未来研究的回顾

Hagop Kantarjian¹, Yifan Zhai², Vivian G Oehler³

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

|April 8, 2025

概括

第三代氨酸激酶抑制剂 (TKI) Olverembatinib在治疗耐其他TKI的慢性髓性白血病 (CML) 中表现出强烈的疗效. 它为患有难以治疗的CML和其他恶性瘤的患者提供了一个新的选择.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

慢性髓性白血病 (CML) 管理已经显著地推进了铁激酶抑制剂 (TKIs),使许多人的预期寿命正常化.
由于ABL1突变的治疗耐药性和不耐受性,包括动脉封闭事件,仍然是CML治疗中的重大临床挑战.

研究的目的:

评估olverembatinib的疗效和耐受性,第三代TKI,在CML耐药或不耐受之前的TKI的患者中.
基于临床前数据,探索olverembatinib在治疗其他血液和固体瘤方面的潜力.

主要方法:

临床试验评估了olverembatinib在重度预先治疗的CML患者中的抗白血病作用,包括那些具有特定突变和对其他TKI耐药性的患者.
临床前模型研究了olverembatinib对多个下游蛋白激酶的抑制.

主要成果:

奥尔韦伦巴替尼在CML患者中表现出强烈的抗白血病活性,这些患者对ponatinib或asciminib有耐药性或不耐受性.
在临床试验中,该药物耐受性良好,其药理动力学特征支持替代日剂量.
临床前研究表明,在急性白血病和胃肠道瘤中具有潜在的应用.

结论:

奥尔韦伦巴替尼布是TKI耐药或不耐受性CML的有效和耐受性良好的治疗选择,包括T315I突变的病例.
目前正在进行的临床试验正在调查olverembatinib针对新诊断的费城染色体阳性急性淋巴细胞白血病,CML和胃肠道 stromal 瘤.

关键词:

慢性骨髓性白血病慢性骨髓性白血病有效性有效性有效性.在安全方面,安全是安全的.这是第三代产品.氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...